Table 6 Accuracy for detecting alteration in human cancer samples

1

025587P

CRC (Stage IIIC)

9

9.7

63%

2609

SNV

PIK3CA

c.1633G > A

p.Glu545Lys

0.31%

0.47%

Y

SNV

ERBB2

c.2524G > A;c.2524G > A;c.2479G > A

p.Val842Ile;p.Val842Ile;p.Val827Ile

0.32%

0.26%

Y

2

025831P

CRC (Stage IIIC)

15.7

20.41

70%

2725

SNV

PIK3CA

c.1633G > A

p.Glu545Lys

0.24%

Not Tested^a

N/A

SNV

KRAS

c.182A > T; c.182A > T

p.Gln61Leu;p.Gln61Leu

0.37%

SNV

APC

c.4031C > G

p.Ser1344*

0.50%

3

025622P

CRC (Stage IVA)

30.05

39.07

66%

2004

SNV

KRAS

c.35G > A; c.35G > A

p.Gly12Asp;p.Gly12Asp

12.35%

15.34%

Y

SNV

APC

c.4012C > T

p.Gln1338*

20.45%

25.69%

Y

CNV

EGFR

N/A

N/A

AMP

AMP

Y

4

019391P

Breast Cancer (stage IIB)

10.25

13.33

71%

2557

None

N/A

N/A

N/A

N/A

None

Y

5

019396P

Breast Cancer (Stage IIB)

10

13

69%

2272

SNV

DDR2

c.2515C > T

p.Arg839Cys

0.27%

Not Tested^a

N/A

6

019388P

Breast Cancer (Stage IIB)

13.15

17.1

70%

2876

SNV

PIK3CA

c.1624G > A

p.Glu542Lys

0.44%

0.83%

Y

7

045931P

NSCLC (Stage IIIB)

16.25

21.13

72%

2836

SNV

TP53

c.892G > T;c.892G > T;c.892G > T;c.859G > T

p.Glu298*;p.Glu298*;p.Glu298*;p.Glu287*

23.47%

28.00%

Y

CNV

EGFR

N/A

N/A

AMP

AMP

Y

8

045903P

NSCLC(Stage IIB)

12.1

66%

2138

SNV

PTEN

c.1027-A > G

N/A

2.04%

2.62%

Y

9

045911P

NSCLC (Stage IIB)

15.1

19.63

70%

2648

None

N/A

N/A

N/A

N/A

None

Y

10

163277P

Prostate Cancer (Stage III)

16.4

21.32

71%

2905

SNV

TP53

c.832C > T; c.832C > T; c.832C > T; c.799C > T

p.Pro278Ser;p.Pro278Ser;p.Pro278Ser;p.Pro267Ser

1.28%

2.01%

Y

11

163445P

Prostate Cancer (Stage IV)

15.75

20.48

66%

2801

None

N/A

N/A

N/A

N/A

None

Y

12

163477P

Prostate Cancer (Stage III)

9

9.5

65%

1689

None

N/A

N/A

N/A

N/A

None

Y